Futura Medical (LSE:FUM) — Market Cap & Net Worth
Market Cap & Net Worth: Futura Medical (FUM)
Futura Medical (LSE:FUM) has a market capitalization of $26.81K (GBX220.32 Million) as of August 7, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31573 globally and #1245 in its home market, demonstrating a -5.25% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Futura Medical's stock price GBX0.38 by its total outstanding shares 581327755 (581.33 Million). See Futura Medical capital spending ratio to understand how much of operating cash flow is reinvested back into capital assets.
Futura Medical Market Cap History: 2015 to 2026
Futura Medical's market capitalization history from 2015 to 2026. Data shows change from $1.99 Million to $26.81K (-32.35% CAGR).
Index Memberships
Futura Medical is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$927.28 Million | 0.00% | #436 of 722 |
Weight: Futura Medical's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Futura Medical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Futura Medical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.05x
Futura Medical's market cap is 0.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $3.96 Million | $170.36K | -$3.70 Million | 23.22x | N/A |
| 2017 | $2.09 Million | $362.73K | -$3.90 Million | 5.77x | N/A |
| 2019 | $981.39K | $31.78K | -$8.92 Million | 30.88x | N/A |
| 2023 | $1.80 Million | $3.10 Million | -$6.51 Million | 0.58x | N/A |
| 2024 | $2.24 Million | $13.93 Million | $1.29 Million | 0.16x | 1.73x |
| 2025 | $78.86K | $1.70 Million | -$9.07 Million | 0.05x | N/A |
Competitor Companies of FUM by Market Capitalization
Companies near Futura Medical in the global market cap rankings as of August 7, 2026.
Key companies related to Futura Medical by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #426 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #546 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #570 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $484.83 |
| #426 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $768.58 |
| #546 | Argen-X | BR:ARGX | $49.55 Billion | €748.60 |
| #570 | UCB SA | BR:UCB | $47.34 Billion | €229.20 |
Futura Medical Historical Marketcap From 2015 to 2026
Between 2015 and today, Futura Medical's market cap moved from $1.99 Million to $ 26.81K, with a yearly change of -32.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX26.81K | -66.01% |
| 2025 | GBX78.86K | -96.48% |
| 2024 | GBX2.24 Million | +24.12% |
| 2023 | GBX1.80 Million | -50.20% |
| 2022 | GBX3.62 Million | +28.00% |
| 2021 | GBX2.83 Million | +162.30% |
| 2020 | GBX1.08 Million | +9.91% |
| 2019 | GBX981.39K | +125.61% |
| 2018 | GBX434.99K | -79.21% |
| 2017 | GBX2.09 Million | -47.11% |
| 2016 | GBX3.96 Million | +99.11% |
| 2015 | GBX1.99 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 6th, 2026 the market cap of Futura Medical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.81K USD |
| MoneyControl | $26.81K USD |
| MarketWatch | $26.81K USD |
| marketcap.company | $26.81K USD |
| Reuters | $26.81K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Futura Medical
Futura Medical plc research, develops, and commercializes pharmaceutical and healthcare products for sexual health. The company's lead product includes Eroxon, a topical gel for the treatment of erectile dysfunction. It also develops WSD4000 for the treatment of sexual dysfunction in women. The company operates in the United Kingdom, the European Union, the United States, and internationally. Fut… Read more